Advinus Moves Ahead With Anti-Diabetes Lead As Tata Group Looks For Strategic Allies
This article was originally published in PharmAsia News
Executive Summary
The Indian venture is exploring financing options even as its lead molecule shows promise.
You may also be interested in...
As Deals Shrink, Indian Companies Ask MNCs To Stay Open For Drug Discovery Partnerships - PharmAsia Summit
SAN FRANCISCO - Consolidation among Big Pharma has resulted in fewer opportunities for smaller companies to out-license newly researched compounds, while the inclination of large companies to selectively work only on "first-to-market" drugs has complicated deal-making for companies with early-stage leads
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.